Tenofovir alafenamide
- Generic Name
- Tenofovir alafenamide
- Brand Names
- Biktarvy, Descovy, Genvoya, Odefsey, Vemlidy
- Drug Type
- Small Molecule
- Chemical Formula
- C21H29N6O5P
- CAS Number
- 379270-37-8
- Unique Ingredient Identifier
- EL9943AG5J
- Background
Tenofovir alafenamide is a novel tenofovir prodrug developed in order to improve renal safety when compared to the counterpart tenofovir disoproxil. Both of these prodrugs were first created to cover the polar phosphonic acid group on tenofovir by using a novel oxycarbonyloxymethyl linkers to improve the oral bioavailability and intestinal diffusion. Tenofov...
- Indication
Tenofovir alafenamide is indicated for the treatment of hepatitis B virus infection in adults and pediatric patients 12 years of age and older with compensated liver disease.
...
- Associated Conditions
- Chronic Hepatitis B Infection, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- Pre-Exposure Prophylaxis (PrEP)
TAF Switch in F3/4 CHB pt With Partial Response to NUC (ESTAB-AFPVR)
- First Posted Date
- 2019-01-09
- Last Posted Date
- 2019-04-26
- Target Recruit Count
- 80
- Registration Number
- NCT03798119
- Locations
- 🇨🇳
Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
TAF Real World Study for Universal Effectiveness
- Conditions
- Interventions
- First Posted Date
- 2018-11-26
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT03752658
- Locations
- 🇨🇳
Department of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳Shulan(Hangzhou) hospitai, Hangzhou, China
🇨🇳First Affiliated Hospital of Nanchang University, Nanchang, China
Effectiveness of TAF in Reducing Clinical Events in CHB Patients Beyond Treatment Indications by Current Guidelines
- First Posted Date
- 2018-11-26
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Young-Suk Lim
- Target Recruit Count
- 780
- Registration Number
- NCT03753074
- Locations
- 🇰🇷
Konkuk University Hospital, Seoul, Korea, Republic of
🇰🇷Kyungpook National University Hospital, Daegu, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
Maternal Screening and Antiviral Therapy in Pregnant Women to Reduce Mother-to-infant Transmission of Hepatitis B Virus
- First Posted Date
- 2018-10-03
- Last Posted Date
- 2020-11-27
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT03695029
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Assessing Virologic Success and Metabolic Changes in Patients Switching From a TDF to TAF Containing Antiretroviral Therapy Regimen
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2019-09-23
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 110
- Registration Number
- NCT03646370
- Locations
- 🇺🇸
Thomas Jeffeson University, Philadelphia, Pennsylvania, United States
The Efficacy and Safety of Nucleos(t)Ide Analogues in the Treatment of HBV-related Acute-on-chronic Liver Failure
- Conditions
- Interventions
- First Posted Date
- 2018-08-21
- Last Posted Date
- 2023-02-09
- Target Recruit Count
- 200
- Registration Number
- NCT03640728
- Locations
- 🇨🇳
The Affiliated Hospital of Yan'an University, Yan'an, China
🇨🇳Hanzhong Infectious Hospital, Hanzhong, China
🇨🇳Weinan Central Hospital, Weinan, China
Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver
- Conditions
- Interventions
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2018-08-23
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 76
- Registration Number
- NCT03604016
Treatment Efficacy and Safety of TDF-TAF Switch Study in South Korea
- Conditions
- First Posted Date
- 2018-06-18
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- The Catholic University of Korea
- Target Recruit Count
- 400
- Registration Number
- NCT03559790
- Locations
- 🇰🇷
The Catholic University of Korea, Daejeon St.Mary's Hosptial, Junggu, Daejeon, Korea, Republic of
Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers (YODA)
- Conditions
- Interventions
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2024-08-13
- Target Recruit Count
- 51
- Registration Number
- NCT03510468
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Entecavir to TAF Switch
- First Posted Date
- 2018-04-05
- Last Posted Date
- 2020-06-25
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 27
- Registration Number
- NCT03489239
- Locations
- 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.